Straumann Holding AG Research and Development Expenses 2012-2024 | SAUHY

Straumann Holding AG annual/quarterly research and development expenses history and growth rate from 2012 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Straumann Holding AG research and development expenses for the quarter ending December 31, 2024 were $M, a NAN% increase year-over-year.
  • Straumann Holding AG research and development expenses for the twelve months ending December 31, 2024 were $0M, a NAN% increase year-over-year.
  • Straumann Holding AG annual research and development expenses for 2024 were $0B, a NAN% decline from 2023.
  • Straumann Holding AG annual research and development expenses for 2023 were $0B, a NAN% decline from 2022.
  • Straumann Holding AG annual research and development expenses for 2022 were $0B, a NAN% decline from 2021.
Straumann Holding AG Annual Research and Development Expenses
(Millions of US $)
2024 $
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $0
2012 $0
2011 $44
Straumann Holding AG Quarterly Research and Development Expenses
(Millions of US $)
2024-12-31
2024-06-30
2021-12-31
2021-06-30
2020-12-31
2020-06-30
2019-12-31
2018-12-31
2017-12-31
2017-06-30
2016-12-31
2016-06-30
2015-12-31
2014-12-31
2013-12-31
2013-06-30
2012-12-31
2012-06-30
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $19.198B $2.845B
The Straumann Group is a global leader in implant and restorative dentistry and oral tissue regeneration. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately on thousand seven hundred ninety people worldwide and its products and services are available in more than sixty countries through its broad network of distribution subsidiaries and partners.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $84.343B 23.08
Becton Dickinson (BDX) United States $65.771B 16.47
Cardinal Health (CAH) United States $33.281B 17.82
Labcorp (LH) United States $19.480B 15.97
Cooper (COO) United States $16.868B 22.37
West Pharmaceutical Services (WST) United States $16.185B 33.17
Align Technology (ALGN) United States $11.630B 22.53
Henry Schein (HSIC) United States $8.505B 14.45
Merit Medical Systems (MMSI) United States $6.219B 30.38
DENTSPLY SIRONA (XRAY) United States $2.973B 8.95
Patterson (PDCO) United States $2.764B 15.94
CONMED (CNMD) United States $1.867B 14.52
STAAR Surgical (STAA) United States $0.870B 0.00
Lifevantage (LFVN) United States $0.183B 20.25
Pro-Dex (PDEX) United States $0.162B 24.67